Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 3Thoracic 2Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Lung Neoplasms 39Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Mesothelioma, Malignant 5Mesothelioma 5Carcinoma 5Ovarian Neoplasms 4Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Non-squamous Non-small Cell Lung Cancer 2Neoplasms by Site 2Lung Diseases 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Pemetrexed × 90 days × Clear all
NCT04956640 2026-05-29

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Active not recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡